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Abstract
Background: Worldwide sugar consumption has tripled during the last fifty years. High sugar intake is associated
with weight gain and increased incidence of diabetes and has been linked with increased cardiovascular mortality.
Reducing the health impact of dietary sugar and poor quality carbohydrate intake is a public health priority.
IminoNorm®, a proprietary mulberry leaf extract (ME), may reduce blood glucose responses following dietary
sugar and carbohydrate intake by reducing absorption of glucose from the gut. Previous research has shown
that ME can reduce blood glucose and improve insulin responses in healthy subjects and also in subjects
with raised fasting blood glucose levels. Mulberry leaf has an excellent safety profile. This pilot study will test
a novel, safe, water soluble product in normoglycaemic adults in the UK to determine if it can reduce glucose
absorption without increasing plasma insulin concentration.
Methods/design: The trial will be a double-blind, individually randomised, four-arm single-dose crossover design to
test the effect of three doses of ME in order to determine efficacy, dose response relationship and gastrointestinal side
effects with respect to placebo. A total of 40 subjects will participate in this study and attend for four visits receiving
each of the four interventions in random order.
Discussion: We aim to test the evidence that mulberry leaf extract can reduce blood glucose without a
disproportionate increase in blood insulin responses in healthy individuals in a high-quality research study
based in the UK. It is hoped that this will lead to further randomised controlled trials and an effective dietary
supplement to lower blood glucose concentrations.
Trial registration: ISRCTN: ISRCTN14597438 (21 April 2015)
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Background
Excess calorie intake including those from sugar can
make a significant contribution to becoming overweight
[1, 2] and thus increase the risk of developing type 2 dia-
betes mellitus (T2DM) [3, 4]. In 2013 a large long-term
European study investigating the effect of diet on health
[5] found an association between the amount of sugary
soft drinks people consumed and their risk of developing
type 2 diabetes. In this study weight gain had a large
effect on diabetes risk, and sugary drinks had a small
effect on diabetes risk even after correcting for body
mass index (BMI). The global rise in T2DM is linked to
the metabolic syndrome (dyslipidemia, hypertension, in-
sulin resistance), and obesity is thought to be one of the
greatest risk factors for metabolic syndrome and T2DM
[6]. Dietary sugars and carbohydrates play a significant
role, as calories from these foods promote fat storage
and hunger [7]. A recently completed review of nutrition
and its impact on T2DM concluded that dietary restric-
tion of carbohydrate intake is the single most effective
approach to manage T2DM [8]. It is estimated that more
than 1 in 17 people in the UK have diabetes (diagnosed
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or undiagnosed) [9], and thus reducing the health im-
pact of dietary sugar and poor quality carbohydrate
intake is a public health priority. Herbal agents could be
quite effective in the management of carbohydrates in
the normal diet and in reducing postprandial blood
glucose [10].
Mulberry (Morus alba) leaves have been used in trad-
itional Chinese medicine (TCM) for several millennia; its
use was first recorded in around 500 AD in the Divine
Husbandman’s Classic of the Materia Medica [11]. It
has also been used for more than 750 years in Japan as
an infusion tea [10]. It is used by some human commu-
nities for food purposes and in several Asian countries
as a herbal tea. Reports have shown that the leaves are
nutritious and non-toxic [12]. The Chinese Ministry of
Health and the Taiwanese Bureau of Food Safety recog-
nise Morus alba leaves as both a food and a medicine
[13]. Mulberry leaf extracts (ME) have a long history of
safe use globally for normalising postprandial blood
glucose, and it is thought that iminosugars such as 1-
deoxynojirimycin (DNJ), a reversible, competitive natural
α-glucosidase inhibitor, are the main active components
responsible for the activities [10].
ME can significantly reduce peak blood glucose levels
and insulin response levels (Kimura et al. [14]; Mudra
et al. [15]), providing protection to the blood glucose
metabolic function of healthy and hyperglycaemic sub-
jects [14, 16]. ME can reduce oxidative stress, glucose
fluctuations during postprandial periods and, more gen-
erally, glucose swings triggering effects on oxidative
stress. By reducing oxidative stress, ME has the poten-
tial to slow down the process of prediabetes to diabetes
and diabetes to developing complications [17, 18].
Long-term administration of ME produced a dose-
dependent decrease in body weight and hepatic lipid
accumulation [18], stimulated skeletal muscle 5′-AMP-
activated protein kinase activity acutely without chan-
ging the intracellular energy status [19], suppressed the
elevation of postprandial blood glucose and cholesterol
in humans [14] and exhibited potential hypoglycaemic
and hypolipidaemic effects in patients with diabetes [20].
Therefore, ME may help reduce blood glucose peaks
caused by the ingestion of sugary or carbohydrate-rich
foods and drinks. Mulberry tea has been shown to suppress
the postprandial rise of blood glucose levels after 90 mi-
nutes of its consumption in subjects with T2DM [21].
The aim of this study is to determine the effect of
three doses of a proprietary water extract of mulberry
leaves standardised to contain 5 % DNJ (IminoNorm®)
versus placebo on blood glucose and insulin responses
when co-administered with 50 g maltodextrin in
normoglycaemic healthy adults. We also aim to deter-
mine the gastrointestinal tolerability of the mulberry
extract using normal (250 mg IminoNorm® containing
12.5 mg DNJ), half (125 mg IminoNorm® containing
6.75 mg DNJ) and also double (500 mg IminoNorm®
containing 25 mg DNJ) the normal dose. Maltodextrin
is a dietary starch with a high glycaemic index, is com-
monly added to many foods and beverages and has
been used as a test carbohydrate in similar studies [15].
We hypothesise that ME will reduce glucose excursions
without causing a disproportionate increase in insulin
release, and thus its ingestion may confer protection
against the development of diabetes, although further




The primary objective is to determine the effect of
three doses of mulberry extract (IminoNorm®) versus
placebo on blood glucose and insulin responses when
co-administered with 50 g maltodextrin in normogly-
caemic healthy adults. We also aim to determine the
gastrointestinal tolerability of the mulberry extract using
normal (250 mg IminoNorm® capsule containing 12.5 mg
1-deoxynojirimycin), as well as half (125 mg IminoNorm®
containing 6.75 mg DNJ) and double (500 mg Imino-
Norm® containing 25 mg DNJ) the normal dose. The ME
(IminoNorm®) is provided by Phynova Group Ltd, UK.
Hypothesis
Our primary hypothesis is that an appropriate dose of
mulberry extract co-administered with oral maltodex-
trin will reduce the incremental area under the curve
for plasma glucose concentration over 120 minutes in
normoglycaemic adults in a dose-dependent manner
when compared to co-administration with placebo.
Our secondary hypothesis is that mulberry extract co-
administered with oral maltodextrin will not dispro-
portionately increase the incremental area under the
curve for plasma insulin concentration over 120 minutes
in normoglycaemic adults compared to co-administration
with placebo.
Study design
A double-blind, randomised, repeat measure, cross-
over design trial will be used to study the glycaemic
response (GR) and insulinaemic response (IR) to three
products: one reference product and three test prod-
ucts. Participants will act as their own controls; that
is, each participant will test all four products. The
trial will be conducted by the Functional Food Centre
at Oxford Brookes University. Ethical approval for the
study has been obtained from the University Research
Ethics Committee (UREC) of Oxford Brookes University,
Faculty of Health and Life Sciences, Headington Campus,
Gipsy Lane, Oxford, OX3 0BP, UK. Participants will be
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given full details of the study protocol and the opportunity
to ask questions. All participants will give written in-
formed consent prior to participation.
Participants
A sample size of 40 participants will be recruited to
allow for any dropouts during the study. Healthy male
and female adult participants (aged 18–60 years) will
be recruited for the study in order to determine if
ME can have an effect on subjects without impaired
glucose tolerance.
Exclusion criteria
The exclusion criteria of the MULBERRY trial are listed
in Table 1.
In addition, participants will be excluded if they are
unable to comply with experimental procedures or do
not follow GR and IR testing safety guidelines.
Suspension criteria
All adverse events will be monitored and recorded
from the time of the screening visit through 24 hours
after treatment visit. Subjects may be excluded or
have the study product discontinued if the investiga-
tor decides discontinuation of the study product is in
the best medical interest of the subject (for example,
due to noncompliance, changes in medications or dietary
supplements, an adverse event or serious adverse event or
a change in medical status) or if the subject requests with-
drawal from the study.
Sample size
A recent study in India (which is yet to be published)
in 12 healthy individuals age 18–25 using 250 mg ME
dose showed a reduction in the glycaemic index of
maltodextrin by 58 % when compared to placebo. A
sample size of 30 would allow over 90 % power to
detect a difference of a similar size. Being more con-
servative and allowing for a smaller difference to be
detected in the lower concentration doses, 30 partici-
pants would still allow at least 80 % power to detect
a difference of 25 % in the incremental Area Under
the Curve (iAUC). In order to account for a potential
loss to follow-up, and the possibility that our sample
size may be inaccurate as it is based on a small pilot
sample, we will therefore recruit 40 participants.
Randomisation
Researchers recruiting the participants will be unaware
of the allocation sequence (concealed allocation). As-
signment of participants to a participant number will
be done according to their chronological order of en-
rolment in the study. The allocated participant number
will identify the participants and their corresponding
intervention sequence. A code break for the randomisa-
tion will be kept by the Principal Investigator and will
only be broken in terms of a serious adverse event.
Blinding (treatment/placebo)
Four products will be tested in this study: one placebo
reference product (four capsules containing 125 mg
microcrystalline cellulose) and three test products con-
taining different doses of mulberry extract (test product
groups receive either 1, 2 or 4 capsules containing
125 mg ME, with either 3, 2 or 0 placebo capsules re-
spectively so that participants always take 4 capsules).
The study products are double blinded to both investi-
gator and subject. Each test/reference product will be
co-administered with 50 g maltodextrin dissolved in
250 mL water. Products will be produced by Phynova
and delivered to the study centre labelled as ’Product
variant A’, ‘Product variant B’, ‘Product variant C’ and
‘Product variant D’ with sealed envelopes labelled with
participant number and the intervention sequence for
the respective participant.
Study period
In each participant, the reference product and test prod-
ucts will be tested in random order on (four) separate
Table 1 Exclusion criteria of the MULBERRY trial
Exclusion criteria
1. Aged < 18 or > 60 years
2. Pregnant or lactating
3. Body mass index (BMI) < 20 kg/m2 and > 30 kg/m2
4. Fasting blood glucose value > 6.1 mmol/L
5. Any known food allergy or intolerance including mulberry extract
6. Medical condition(s) or medication(s) known to affect glucose
regulation or appetite and/or influence digestion and absorption
of nutrients
7. Known history of diabetes mellitus (type I/II) or the use of
antihyperglycaemic drugs or insulin to treat diabetes and related
conditions
8. Use of steroids, protease inhibitors or antipsychotics (all of which
have major effects on glucose metabolism and body fat distribution)
9. Current oral hypoglycaemic use
10. Symptomatic IBS
11. History of renal or liver diseases
12. History of clotting or bleeding disorders
13. Taken antibiotics in last 3 weeks prior to screening
14. Taking daily medications or dietary supplements that are not suitable
for the study in the opinion of the PI
15. Anaemia
16. Subject to a major medical or surgical event requiring hospitalization
within the preceding 3 months
17. Current participation in another clinical study.
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days, with at least a two-day gap between measurements
to minimise carry over effects. The study schedule is
summarised in Table 2.
Outcomes
Primary outcome:
 iAUC for plasma glucose concentration over
120 minutes.
Secondary outcomes:
 iAUC for plasma insulin concentration over
120 minutes.
 Gastrointestinal tolerability – abdominal bloating
may be experienced due to reduced carbohydrate
absorption. Gastrointestinal symptoms will be
measured via questionnaire for 24 hours following
each study visit. Subjects will use a five-point scale
to rate stool consistency for each bowel movement
for 0–24 hours after the study product consumption.
The five-point scale includes: 1 = watery, 2 = loose/
mushy, 3 = soft, 4 = formed, 5 = hard. Frequency and
intensity will be set to a 10-cm line scale (0 representing
’Absent’ for frequency and ’Usual’ for intensity; 10
representing ’More than usual’ for frequency and
’Severe’ for intensity).
Recruitment
Participants will be recruited following local advertise-
ments, and all participants will be given full details of
the study protocol and the opportunity to ask questions.
All participants will give written informed consent prior
to participation and will be paid £10 per visit, on
completion of all four visits. This has been determined
as an appropriate amount to cover travel costs and the
time spent during each visit.
Procedures/study schedule
The study will be conducted by Good Clinical Practice
(GCP) certified researchers. The reference product and
test products will be administered to participants in a
randomised, repeated measures design. On the day
prior to a test, participants will be asked to restrict their
intake of alcohol and caffeine-containing drinks and to
restrict their participation in intense physical activity
(for example, long periods at the gym, excessive swim-
ming, running, aerobics). Participants will also be told
not to eat or drink after 10:00 pm the night before a
test, although water will be allowed in moderation.
Participants will be studied in the morning after an
overnight fast. Participants will consume the products
at a comfortable pace, within 5 minutes. The reference
product and test products will be served with 50 g
maltodextrin dissolved in 250 mL water. Participants
will remain sedentary during each test session and will
not consume any additional food or fluid. Participants
will be instructed to record stool consistency for the
first bowel movement after their visit and the frequency
and intensity of gastrointestinal symptoms for 0–24
hours after the study product consumption.
All anthropometric measures will be taken, using stand-
ard methods, in the morning, after an overnight fast.
 Height and weight
 BMI will be calculated using the standard formula:
weight (kg)/height (m2)
 Waist and hip circumference
The glycaemic response method used is adapted from
that described by Brouns et al. [22] and is carried out
in accordance with the ISO 26642:2010 standards.
Blood measurements will be taken at −5 minutes and
0 minute before consumption of the reference product/
test products and the baseline value taken as a mean of
these two values. Further blood measurements will be
taken at 15, 30, 45, 60, 90 and 120 minutes after starting
to eat. Blood glucose will be measured using the Hemo-
Cue Glucose 201+ analyser (HemoCue® Ltd). The same
time points will be used for determining insulin levels. At
each test time point, 300 μL of capillary blood (from finger
pricks) will be obtained. Finger pricks will be made using
the Unistik 3 single-use lancing device (Owen Mumford,
Woodstock, UK) and blood will be collected into chilled
Microvette® capillary blood collection tubes treated with
dipotassium EDTA (CB 300 K2E; Sarstedt Ltd., Leicester,
UK). The Microvette® tubes will then be centrifuged and
200 μL of the supernatant plasma obtained. Insulin

















● ● ● ●
Physical exam
(BMI, waist circ. etc.)
● ● ● ●
Consume product/placebo
+ drink
● ● ● ●
Finger-prick glucose and
insulin testing
● ● ● ●
GI questionnaire ● ● ● ●
Adverse event monitoring ● ● ● ●
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concentrations in the plasma samples will be determined
by electrochemiluminescence immunoassay using an au-
tomated analyzer (Cobas® E411; Roche diagnostics, Bur-
gess Hill, UK). The Cobas® system is a reliable method of
plasma insulin determination. The unit of measurement is
μU/mL. Sufficient blood is taken to enable two sets of
analyses to be performed at every time point, thus greatly
reducing the likelihood of missing data.
Statistical analysis
This is the first rigorous study of IM and should there-
fore be considered as a pilot study from a statistical
perspective. We will calculate the incremental area
under the curve for all four study products and com-
pare using repeated measures ANOVA to determine
whether there is a statistically significant difference in
plasma glucose levels and in secondary outcome meas-
ure over the 120-minute period. All models will control
for the possible confounding effects of sex and BMI.
The presence/absence of gastrointestinal symptoms in
the 24 hours following the study visit will be assessed
using logistic regression models. We anticipate a low
likelihood of missing data (as sufficient blood is taken
for a second analysis to be performed if the first ana-
lysis fails), and our glucose values will be measured in
real time. We anticipate monophasic or biphasic glu-
cose and insulin curve responses and will use a second
order interpolation method for missing data, provided
that no other data is missing from the two neighbour-
ing time points at either side of a missing data set and
that the baseline and end data values are obtained. If
the baseline or endpoints are missing or more than one
data point within five neighbouring time points, this
data set will be deemed unsuitable and will not be in-
cluded in the analysis.
Discussion
In this paper, we have suggested the clinical trial design
of a dietary supplement to reduce glucose excursions
without a disproportionate increase in insulin release.
This pilot study will influence further work on a larger
scale RCT. In this study we aim to confirm the standard
dose of IminoNorm that can be consumed with food. In
addition, we aim to determine the magnitude of clinical
effect and to measure the frequency and intensity of any
gastrointestinal side effects. Based on the results, we will
aim to design a larger RCT to investigate the protective
effect of ME on the development of prediabetes and dia-
betes in at-risk individuals or the population as a whole.
The treatment effect size may be used to determine the
sample size of a larger study based on similar studies on
the prevention of T2DM. As mentioned previously, ME
may also have a positive effect on lipid profiles, and we
may decide to include further endpoints in future larger
trials. Glucose-lowering agents show ethnic variations;
thus, future work should include assessment in more
ethnically diverse populations.
Trial status
We have now finished recruiting and most of the partici-
pants have completed all four visits.
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